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2Condensation
Serum relaxin levels are reduced in pregnant women with a history of 
recurrent miscarriage, and correlate with maternal uterine artery Doppler 
indices in first trimester.
3ABSTRACT
Objectives: Defective implantation is a mechanism for recurrent pregnancy loss 
(RPL). We sought to determine whether the serum expression of human relaxin 2 
(RLX) is impaired in women with a history of RPL.
Study Design: Employing a prospective case-controlled design we studied 20 
pregnant women with a history of RPL and 20 age-matched women with no history of 
RPL (NRPL). We measured serum relaxin 2 levels by ELISA at 6-8, 10-12, 20, 34 
wks gestation and in cord blood, and maternal uterine artery Doppler resistance 
index (RI) at ≥ 10 wks gestation.
Results: Relaxin rose to a peak at 12 wks, and gradually declined towards term. At 
all gestations, women with a history of RPL had lower RLX levels than women 
without. At 10-12 wks uterine artery, uterine artery RI correlated with serum RLX for 
both RPL and NRPL and the presence of a notched waveform in the NRPL group 
was associated with higher RLX levels than the absence of a notch (mean 2.1 vs. 
1.3ng/ml, P < 0.05 respectively), and also at 20 wks (2.1 vs. 0.95 ng/ml, P < 0.05 
respectively), but did not differ in the RPL group. Umbilical venous RLX was 4-fold 
higher in the RPL group than the NRPL group.
Conclusion. Women with a history of RPL demonstrate attenuated levels of serum 
RLX across all pregnancy trimesters. How dysregulated RLX metabolism may 
contribute to adverse pregnancy outcome in RPL requires further investigation.
Key words: relaxin, pregnancy, recurrent miscarriage, Doppler, implantation.
4INTRODUCTION.
Recurrent pregnancy loss (RPL) is a distressing clinical problem which affects 1% of 
all women. Although no cause is found in the majority of cases, it has been 
associated with the antiphospholipid syndromes (1), immunological “intolerance” from 
altered function of endometrial natural killer (NK) cells (2), the polycystic ovary 
syndrome (3) and insulin resistance (4). A common mechanism for fetal wastage in 
RPL is defective implantation. (2)
Even when pregnancy following RPL is ultimately successful, placental function may 
still be compromised, with higher rates of adverse pregnancy outcomes being 
reported. (5) Abnormal placentation may be associated with high resistance index 
(RI) in the uterine artery (UA) Doppler waveform, a finding noted to have high 
predictive value for conditions associated with placental dysfunction such as pre-
eclampsia, fetal growth restriction and placental abruption. (6)
Several serum markers are altered in women with RPL but do not accurately predict 
repeat miscarriage.  These markers include inhibin A (7), glycodelin (8) and 
microparticles (9). When RPL is associated with the antiphospholipid (APS) and 
polycystic ovary (PCOS) syndromes, markers of insulin resistance (4) are impaired. 
Leptin expression levels are low in women who subsequently miscarry (10) but do 
not discriminate between such pregnancies and others. 
Relaxin (RLX) plays a key role in reproduction, being involved in implantation, 
embryogenesis, placental development and prelabour uterine preparation. (11, 12)
Relaxin genes are over-expressed in preterm rupture of fetal membranes (13) and 
change with the remodelling of the extracellular matrix prior to parturition. (14)
However RLX expression during pregnancy to women with a history of RPL has not 
been studied.
5We compared RLX levels in serum and cord blood of pregnant women with a 
significant history of RPL to those women with no history of RPL, and determined
whether serum RLX correlates with UA Doppler indices or pregnancy outcome.
6MATERIALS AND METHODS
Subjects. Twenty women with a history of RPL (defined as the loss of three or more 
consecutive pregnancies before 24 wks) were consecutively recruited from the 
pregnancy RPL clinic. This data set comprised women with idiopathic RPL, the APS, 
or a history of PCOS. We included only women whose RPL was not attributable to 
uterine tumours, uterine malformations or proven cervical weakness. A control group 
of 20 age-matched women with no history of RPL or an identified association with 
RPL was also recruited from the booking antenatal clinics. We excluded women who 
smoked cigarettes from the study. Sample sizes were determined on the basis of a
previous study that measured serum RLX levels and demonstrated significant 
differences between a group of women with abnormal pregnancies and another with 
normal early pregnancies. (15) We estimated that 20 subjects in each study arm 
would detect a 10% difference in RLX levels between groups with 80% power at the 
95% confidence level. Written informed consent was obtained from each study 
participant. Ethical permission was obtained from the South Sheffield Research 
Ethics committee.
Study design: Investigations were carried out on participants at 6-8, 10-12, 20, and 
34 wks gestation. At each visit 10mls of blood was obtained. A further blood sample 
was obtained from the umbilical cord vein immediately after delivery of the baby. 
Samples were transported to the laboratory immediately and centrifuged to obtain 
serum which was aliquoted and stored at -80°C for subsequent batch analysis. At ≥ 
10 wks, fetal biometry and UA Doppler indices were measured by transabdominal 
ultrasound. (16)
Laboratory analysis: Serum RLX was measured using the Quantikine Human 
Relaxin-2 Immunoassay kit (Catalog Number DRL200, R&D systems, Minneapolis, 
7USA). This assay is based on the quantitative sandwich enzyme technique and 
employs a monoclonal antibody specific for Human Relaxin-2 pre-coated onto a 
microplate. Standards and samples are pipetted into the wells and any Relaxin-2 
present is bound by the immobilized antibody. Following addition of an enzyme-
linked polyclonal antibody specific for Relaxin-2 a substrate solution is added to to 
enable colour to develop in proportion to the amount of Relaxin-2 bound in the initial 
step. The assay measures the concentration range 2–250 pg/mL. The inter-assay 
coefficient of variation (CV) for this kit is 10.2% and 5.5% for 40 and 220 pg/mL 
relaxin respectively, and the intra-assay CV is 4.7% and 2.3% for 34 and 206 pg/mL, 
respectively. All samples were blinded for the analyst and measured simultaneously. 
Samples above 250 pg/mL were diluted and re-analysed. Quantitation of serum RLX 
has been previously described. (15, 17)
Doppler studies: Maternal UA Doppler velocimetry was evaluated using a pulsed 
wave technique at each visit ≥10 wks by transabdominal ultrasonography. The RI 
has been shown to be the most repeatable and least variable of the UA Doppler 
indices. (16). The average RI of the left and right UA Doppler waveform was used for
tests of association. The presence of a dicrotic notch in either or both uterine arteries 
was also used compare RLX levels in both study groups. All clinical details, including 
the pregnancy outcome for both groups, were recorded. 
Outcome measures: The primary outcome measure was serum RLX and UA RI 
indices. Clinical outcomes that were tested for association with serum RLX and 
uterine RI were spontaneous miscarriage, premature delivery before 34 wks 
gestation, small for gestational age (birth weight less than the 10th customized 
centile for gestation, (18)), placental abruption and stillbirth.
8Data analysis: Serum RLX and UA Doppler indices were compared by one-way 
ANOVA, the student t-test or the Mann-Whitney U test with appropriate post hoc 
correction (the Bonferroni test) for repeated measures and multiple comparisons.
Binary logistic regression analyses and the area under the Receiver Operator 
Characteristic (ROC) Curves were used to test association between RLX and UA RI
and clinical outcome variables. Where data regarding cord blood RLX were missing a 
listwise deletion approach was adopted for analysis.
RESULTS:
General clinical and laboratory details. Table 1 summarises the clinical details of 
all participants and the outcome of their pregnancies. Of the 20 participants with a 
history of RPL, 12(60%) had idiopathic RPL, 5(25%) had the APS, and 3(15%) had 
the PCOS associated with suspected luteal phase deficiency. All those with the APS 
were treated with low molecular weight heparin (LMWH) and low-dose aspirin 
throughout pregnancy. There was no significant difference in the rates of preterm 
birth, prelabour rupture of fetal membranes and miscarriage between study groups 
and between aetiological association subtypes in women with RPL. 
Serum relaxin levels did not differ with maternal gravidity or parity. At all gestational 
time points, except at 6-8 wks, RLX was significantly lower in the RPL compared to 
the NRPL group (Table 1). Amongst women with RPL serum RLX levels did not differ 
by cause of miscarriage or by treatment with aspirin or LMWH (data not shown). In 
NRPL but not RPL, RLX at 6-8 wks markedly correlated with levels at 12 and 20 wks 
gestation. 
Stepwise logistic regression analysis (factors included in model: maternal age and 
body mass index, serum relaxin) demonstrated that serum RLX in RPL was lower 
9than in NRPL group at 10-12wks gestation (regression coefficient -1.1, SE 0.5, OR 
0.33, 95% CI 0.12, 0.95, P < 0.05), at 20 wks gestation (regression coefficient -2.0, 
SE 0.9, OR 0.14, 95% CI 0.03, 0.75, P < 0.05), and at 34 wks gestation (regression 
coefficient -1.3, SE 0.7, OR 0.26, 95% CI 0.07, 1.06, P = 0.05). The association 
between low RLX and a history of RPL is depicted in Figure 1 as Receiver Operator 
Characteristic (ROC) curves: at 10-12 wks gestation RLX ≤ 1.7ng/ml was best 
associated with a history of RPL [sensitivity 95%, specificity 42%, LR+ 1.64 95% CI 
1.0 ‑ 2.8, LR- 0.12, 95% C1 0.02 ‑ 0.8, P < 0.05)] whilst at 20 wks gestation RLX ≤ 
0.7ng/ml was best associated with a history of RPL [sensitivity 79%, specificity 61%, 
LR+ 2.0 95% CI 1.3 ‑ 3.1, LR- 0.3 95% C1 0.3 ‑ 1.0, P < 0.01)]. Although mean RLX 
was lower in RPL than NRPL at 6-8 and at 34 wks, the levels were not 
significantly associated with a history of RPL.
Correlation of serum RLX levels with uterine artery resistance index. This is 
summarised in Table 2. At 10-12 wks gestation there was moderate positive 
correlation (correlation coefficient between 0.4 and 0.6) between the average UA RI 
and serum RLX for both RPL and NRPL (Figure 2). The incidence of uni- or bilateral 
notching did not differ between RPL and NRPL (Table 1). However at 10-12 wks 
mean ± SE serum RLX was higher in the NRPL group with UP notching (2.1±0.4 
ng/ml) compared to those without UP notching (1.3±0.2 ng/ml, P < 0.05), but did not 
differ by notching in those with a history of RPL (1.1±0.2 vs. 0.9±0.2 ng/ml). Similarly 
at 20 wks gestation serum RLX was higher in the NRPL group with UP notching 
(2.1±0.7 ng/ml) compared to those without UP notching (0.95 ± 0.1 ng/ml, P < 0.05) 
but did not differ in those with a history of RPL (0.6 ± 0.1 vs. 0.4 ± 0.21 ng/ml).  In 
neither group did RLX differ with UA notching at 34 wks gestation. In both groups UA
pulsatility index did not correlate with serum RLX at any gestation.
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Serum RLX levels and pregnancy outcomes.
Serum RLX at 34 wks gestation was not significantly different in women who had 
prelabour rupture of membranes (mean ± SE 0.8 ±0.1) compared to women who 
went into labour with intact membranes (0.9 ±0.2 ng/ml), and did not correlate with 
fetal birth weight or gestational age at delivery for either group. 
Cord blood relaxin levels. Cord blood was obtained in 15 (75%) RPL and 13 (60%)
NRPL participants: RLX levels were 4-fold higher in the RPL group than the NRPL 
group but this did not attain statistical significance (Table 1) but did not correlate with 
antenatal RLX levels, Doppler indices, fetal birth weight, or gestational age at 
delivery. In RPL, women with prelabour rupture of membranes showed a trend 
towards higher cord RLX levels than women without prelabour amniorrhexis (0.16 ± 
0.11 vs. 0.04 ± 0.02 ng/ml, P = 0.15 respectively) whilst in the NRPL group cord RLX 
did not appear to differ by timing of fetal membrane rupture (0.26 ±0.01 vs. 0.20 
±0.00, P = 0.48 respectively).  
11
COMMENTS.
This is the first report that serum relaxin levels are decreased throughout pregnancy 
in women with a history of RPL compared to those without such history. Additionally 
we noted correlation between 1st and 2nd trimester serum RLX levels in the women 
without a history of RPL but not in the group with a history of RPL, suggesting that 
dysregulation of relaxin metabolism may be important in the pathogenesis of 
recurrent early pregnancy failure. The positive correlation of serum relaxin with UA RI 
at 10-12 wks is consistent with a putative role for this hormone in the early regulation 
of uteroplacental haemodynamics. (19)
Our gestational changes in serum RLX levels confirm the only previous report: in 
normal pregnant women serum RLX concentrations increased during the first 14 wks 
of pregnancy, decreasing thereafter until about 24wks when it then remained 
constant, with no changes evident immediately before or during spontaneous 
delivery. (15) One study reported lower RLX levels during miscarriage and ectopic 
pregnancies compared to viable early pregnancies (15) whilst another reported 
unchanged levels. (17) We could not confirm or refute these observations as only 
one woman in our RPL group miscarried. Any temporal relationship between 
changes in serum RLX levels and clinical pregnancy failure remains to be 
determined. 
Reduced serum RLX2 in women with a history of RPL is likely to mirror lower 
production in reproductive tract tissue, the primary site of relaxin production and 
action. Increasing blood flow to endometrial or placental tissue requires neo-
vascularisation promoted by the key angiogenic growth factors vascular endothelial 
growth factor (VEGF) and placental growth factor. (20) Relaxin upregulates VEGF 
and increases blood flow to the endometrium and other reproductive tract tissue (21). 
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Reduced functional activity of RLX from the corpus luteum (22) is therefore likely to 
contribute to defective endometrial implantation and recurrent pregnancy failure. We 
hypothesise that a critical level of defective RLX activity is required before a 
pregnancy fails.  Consequently the pregnancies to our cohort of women with a history 
of RPL may have had favourable outcomes because the reduced expression of RLX 
did not attain the critical levels required to result in miscarriage or other adverse 
outcomes. 
Serum relaxin levels peak by the end of the first trimester, coinciding with the switch 
of RLX synthesis from the systemic corpus luteum to the paracrine placenta and fetal 
membranes. The order of expression of RLX gene transcripts is: corpus luteum of 
pregnancy > corpus luteum of the cycle > placenta and prostate > decidua parietalis 
(23), somewhat consistent with our temporal observations through pregnancy. The 
reported wide variations in expression levels of RLX genes from tissue to tissue and 
within each tissue within the term placenta (23) may explain the lack of correlation at 
34 wks between serum RLX levels and UA Doppler indices on the one hand and 
serum RLX and pregnancy outcome on the other. Furthermore, RLX has paracrine 
functions within tissues close to its site of production. Systemic RLX, derived mainly 
from the corpus luteum (24), may therefore not parallel local functional levels in the 
placenta, decidua or fetal membranes. (25) We did not measure serum RLX 
immediately prior to labour because RLX levels do not appear to change significantly 
at term and prior to parturition. (15)
We noted a 4-fold increase in cord blood RLX levels in the women with a history RPL 
compared to those without. However our data only approached statistical significance 
possibly because our sample size was small. It may be hypothesized that deranged 
maternal RLX metabolism associated with RPL leads to a compensatory increase in 
fetal relaxin expression through as yet unidentified regulatory feedback mechanisms 
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similar to the fetal hyperinsulinaemia/hypoglycaemic response to maternal 
hyperglycaemia. Interestingly relaxin belongs to the insulin family of peptide 
hormones. 
We observed modestly increased cord blood relaxin levels in the subset of the RPL 
group who had prelabour membrane rupture. A similar increase has been described 
in preterm decidual tissue and placental syncytiotrophoblast from women with 
preterm premature rupture of membranes compared to those with intact membranes. 
(13) Our study of systemic rather than local tissue RLX levels may have precluded 
identification of any relationship between RLX expression and timing of fetal 
membrane rupture. 
We studied the expression levels of human RLX2 rather than RLX1 because only the 
former isoform appears to have a functional role in reproductive tract tissue. (26). It is 
unlikely that the serum RLX that we measured originated from non-gestational 
tissues as gestational relaxin is only expressed in placental syncytiotrophoblast, 
decidua, and corpus luteum. (27) In the nonpregnant state, relaxin was only 
demonstrable in the corpus luteum and secretory phase endometrium and not in 
myometrium, cervix, vagina, and Fallopian tubes.
We did not exclude women whose previous miscarriages were due to embryonic 
chromosomal aberrations because this information was not always available. Such 
chromosomal aberrations in past pregnancy losses may have confounded the 
results. Only one patient in our study group subsequently miscarried, suggesting an 
extremely high live birth rate or 95%. The reason for the highly successful birth 
outcome in our cohort is unclear but may be attributable in part to our care 
philosophy that spans from conception to birth in one unified service provided by 
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specialist nurses, midwives, gynaecologists with an interest in RM and fetal medicine 
specialists. 
In conclusion, we have demonstrated that serum relaxin levels are reduced across all 
gestations of viable pregnancies to women with a history of RPL. Taken together with 
studies that show reduced relaxin levels in abnormal and non-viable pregnancies, our 
data suggest that dysregulation of RLX functional expression may play a role in 
habitual early pregnancy failure possibly by suppressing endometrial and placental 
angiogenesis. Further studies are required to explain these observations.
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TABLES/FIGURE CAPTION LIST.
Table I. Subject characteristics and pregnancy outcome.
Table 2. Correlation matrix, serum relaxin levels vs. uterine artery Doppler resistance 
index in women with a history of RPL and a control group of women with no history of 
RPL (NRPL).
Figure 1. ROC curves depicting association of serum relaxin levels at various 
gestations with a history of RPL (RLX human relaxin 2, AUC Area under the Curve, * 
P < 0.05, ** P < 0.01)
Figure 2. Scatter diagram showing correlation of average uterine artery resistance 
index with serum RLX levels at 10-12wks (open circles: women with history of RPL, 
triangles: women with no history of RPL).
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Table 1 Subject characteristics and pregnancy outcome.
History of recurrent 
pregnancy loss
No history of recurrent
pregnancy loss
P value
n 20 20
Median (range) age (yrs) 32.5 (20 – 43) 31.0 (24–41) 0.8
Body mass index 27.3 (5.5) 25.7 (5.8) 0.3
Mean (SE) gestational age at 
delivery (weeks)
38.4 (1.0) 38.3 (1.1) 0.95
Delivery before 37 weeks, n (%) 3 (15) 3 (15) NS
Mean (SE) birth weight (g) 3040 (206) 3364 (216) 0.15 
Pre-labour spontaneous rupture 
of fetal membranes, n (%)
5 (25) 6 (30) NS
Infant birth weight <2500g, n (%) 7 (35) 3 (15) 0.15 
Small for gestational age (birth 
weight <10th centile)
5 (25%) 0 0.048
Still births 0 0
Miscarriage, n (%) 1(5) 0
Mean (SE) serum RLX levels in 
ng/ml)
6-8wks 1.06 (0.14) 1.49 (0.21) 0.09
10-12 wks 1.07 (0.11) 1.62 (0.21) 0.03
20 wks 0.59 (0.09) 1.14 (0.18) 0.01
34 wks 0.58 (0.09) 1.07 (0.21) 0.03
Cord serum 0.08 (0.04) 0.02 (0.00) 0.21 
Mean (SE) uterine artery 
Doppler resistance index
10-12 wks 0.66 (0.03) 0.61 (0.04) 0.47
20 wks 0.64 (0.10) 0.55 (0.03) 0.76
34 wks 0.54 (0.02) 0.48 (0.02) 0.12
Uterine artery Doppler 
(diastolic notch, n %)
10-12 wks 8 (40) 8 (40) 1
20 wks 6 (30) 4 (20) 0.43
34 wks 3 (15) 1 (5) 0.55
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Table 2. Correlation matrix, serum relaxin levels vs. uterine artery Doppler resistance index in women with a history of RPL and a control 
group of women with no history of RPL (NRPL). Data shown are coefficients of correlation.
RLX at 6 -8wks RLX at10-12wks RLX at 20wks RLX34wks Cord blood RLX UA RI,10-12wks UA RI, 20wks
RPL NRPL RPL NRPL RPL NRPL RPL NRPL RPL NRPL RPL NRPL RPL NRPL 
1. RLX at 6 -
8wks
2. RLX at10-
12wks
0.4 0.7(**)
3. RLX at 
20wks
0.2 0.9(**) 0.7(**) 0.7(**)
4. RLX34wks 0.3 0.8(**) 0.9(**) 0.8(**) 0.7(**) 0.9(**)
5. Cord blood 
RLX
-0.1 0.3 -0.1 0.6(*) 0.1 0.3 -0.1 0.3
6. Uterine 
artery RI,10-
12wks
0.3 0.3 0.5(*) 0.5(*) 0.5(*) 0.4 0.2 0.5(*) -0.01 0.5
7. Uterine 
artery RI, 
20wks
0.6(*) 0.3 0.3 -0.1 0.2 0.1 0.3 -0.0 -0.1 -0.2 -0.3 -0.3
8. Uterine 
artery RI, 
34wks
0.2 -0.1 0.1 -0.4 0.0 -0.2 0.2 -0.2 -0.6 (*) -0.3 0.2 -0.2 0.1 0.1
Correlation coefficient is significant: * at the 0.05 level,** at the 0.01 level. RI resistance index, RPL recurrent pregnancy loss.
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